Feeds:
Posts
Comments

Posts Tagged ‘hormonal therapy’

NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>

Read Full Post »

JULY 17: HERALD TRIBUNE.COM:  In his letter “Prostate cancer article needs clarification,” Dr. Michael J. Dattoli claims that intensity modulated radiation therapy (IMRT) is the preferred option for treating prostate cancer.

Not surprising, since that is what he does at his center, writes Mark H. Ebell, deputy editor, American Family Physician, and associate professor, College of Public Health, University of Georgia.

“Unfortunately, there is not a single randomised controlled trial comparing IMRT with other approaches to treatment, such as traditional radiation therapy, hormonal therapy and watchful waiting.” READ MORE>

Read Full Post »

JUNE 12: URO TODAY: A study has been done on whether the risk of death is associated with the time to testosterone recovery (TTR) after radiotherapy (RT) and hormonal therapy (HT) for prostate cancer (PCa). The results show that a longer TTR after RT plus 6 months of HT for unfavourable-risk PCa is associated with a lower risk of death in men with no or minimal co-morbidity. READ MORE>

Read Full Post »